Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (2406)	2/18/1998 11:22:00 PM
From: Brander	Read Replies (1) \| Respond to of 7041

Bradpalm, With all due respect, "Sounds like apomorphine has a better chance of a NDA submission and FDA approval than Vasomax" sounds like a profound overstatement. First, lets see what the actual results of the trials are before we attempt to trash it. Second, if ZONA has to do part, or even the entire, trial over again, it wouldn't be the first time a biotech had to do a Phase III trial again. It is not the end of the world, or even ZONA. Phentolamine might have some usefulness in the widespread problem of impotence. I am giving ZONA a chance to prove it. If it is a fraud, like you and the shorts claim, it will never get through the FDA. I am not convinced that ZONA is fraudulently trying to push the Vasomax story nor am I convinced that Vasomax is effective. I do think, as quoted before "...the jury is still out..." on Phentolamine, and I will continue to follow ZONA. It is an interesting speculative company.